Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
| Autor: | Rehan M. Hussain, Andrea Neal, Nicolas A. Yannuzzi, Kevin H. Patel, Siya Huo, Seenu M. Hariprasad, Sumit P. Bhatia |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Ophthalmology, Vol 13 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2515-8414 25158414 |
| DOI: | 10.1177/25158414211055964 |
| Popis: | Background: Some patients with neovascular age-related macular degeneration (nAMD) have persistent intraretinal/subretinal fluid (IRF/SRF) despite being treated with anti-VEGF agents. There is limited data on efficacy of switching to intravitreal brolucizumab (IVBr) in these patients. Purpose: To determine anatomic and visual outcomes of eyes with nAMD treated with for persistent IRF/SRF. Methods: Retrospective series of eyes with nAMD treated initially with aflibercept (IVA, n = 48) and bevacizumab (IVBe, n = 10), then switched to IVBr for persistent IRF/SRF. Results: In the IVA-IVBr group, a mean of 42 days after one IVBr, mean logMAR changed from 0.50 to 0.49 ( p = 0.73) and mean CSFT changed from 340 to 305 µm ( p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|